Premium
Control of asthma by omalizumab: the role of CD 4 + Foxp3 + regulatory T cells
Author(s) -
Amat F.,
Tallon P.,
Foray A. P.,
Michaud B.,
Lambert N.,
SaintPierre P.,
Chatenoud L.,
Just J.
Publication year - 2016
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.12839
Subject(s) - humanities , medicine , omalizumab , allergy , library science , art , immunology , computer science , immunoglobulin e , antibody
International audienceAllergic asthma is an inflammatory disease of the airways, resulting from an inappropriate immune response to inhaled allergens, which involves multiple inflammatory cells and mediators that contribute to airway hyper-responsiveness. Omalizumab is a monoclonal antibody, specifically directed to the C-Epsilon3 domain of immunoglobulin E (IgE), indicated as an additional therapy in severe allergic asthma [1]. Impaired function of regulatory T cells (Treg) is incriminated in the aberrant asthma inflammatory response [2]